tiprankstipranks
Trending News
More News >
BioVaxys Technology (TSE:BIOV)
:BIOV

BioVaxys Technology (BIOV) Price & Analysis

Compare
18 Followers

BIOV Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

10.05%<0.01%89.95%
10.05% Insiders
Mutual Funds
<0.01% Other Institutional Investors
89.95% Public Companies and
Individual Investors

BIOV FAQ

What was BioVaxys Technology’s price range in the past 12 months?
BioVaxys Technology lowest stock price was C$0.03 and its highest was C$0.08 in the past 12 months.
    What is BioVaxys Technology’s market cap?
    BioVaxys Technology’s market cap is $11.66M.
      When is BioVaxys Technology’s upcoming earnings report date?
      BioVaxys Technology’s upcoming earnings report date is Jun 26, 2025 which is in 17 days.
        How were BioVaxys Technology’s earnings last quarter?
        BioVaxys Technology released its earnings results on Mar 31, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
          Is BioVaxys Technology overvalued?
          According to Wall Street analysts BioVaxys Technology’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does BioVaxys Technology pay dividends?
            BioVaxys Technology does not currently pay dividends.
            What is BioVaxys Technology’s EPS estimate?
            BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does BioVaxys Technology have?
            BioVaxys Technology has 291,525,200 shares outstanding.
              What happened to BioVaxys Technology’s price movement after its last earnings report?
              BioVaxys Technology reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
                Which hedge fund is a major shareholder of BioVaxys Technology?
                Currently, no hedge funds are holding shares in TSE:BIOV

                Company Description

                BioVaxys Technology

                BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
                Similar Stocks
                Company
                Price & Change
                Follow
                Innovotech
                Core One Labs
                Tetra Bio-Pharma
                BetterLife Pharma
                Glow LifeTech
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis